Share

December 2016; 3 (6) ArticleOpen Access

Risk of relapse after natalizumab withdrawal

Results from the French TYSEDMUS cohort

Caroline Papeix, Sandra Vukusic, Romain Casey, Nadine Debard, Bruno Stankoff, Serge Mrejen, Zoe Uhry, Eric Van Ganse, Anne Castot, Michel Clanet, Catherine Lubetzki, Christian Confavreux, For the TYSEDMUS and OFSEP Group
First published October 28, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000297
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1368

Share

Article Information

vol. 3 no. 6 e297
DOI: 
https://doi.org/10.1212/NXI.0000000000000297
PubMed: 
27844037
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 8, 2016
  • Accepted in final form September 23, 2016
  • First Published October 28, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Caroline Papeix, MD*,
    2. Sandra Vukusic, MD, PhD*,
    3. Romain Casey, PhD,
    4. Nadine Debard,
    5. Bruno Stankoff, MD, PhD,
    6. Serge Mrejen, MD,
    7. Zoe Uhry,
    8. Eric Van Ganse, MD, PhD,
    9. Anne Castot, PhD,
    10. Michel Clanet, MD, PhD,
    11. Catherine Lubetzki, MD, PhD‡,
    12. Christian Confavreux, MD, PhD†,‡;
    13. For the TYSEDMUS and OFSEP Group
  1. Caroline Papeix, MD*,
    2. Scientific Advisory Boards:

    1. bayer sherring novartis teva

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. educational activities : bayer sherring (2010), biogen idec (2005-2014), novartis (2009-2015), sanofi genzyme (2008-2015), Merk serono (2009-2012) Roche (2009-2015)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Sandra Vukusic, MD, PhD*,
    3. Scientific Advisory Boards:

    1. Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancy in board for Biogen-Idec, Geneuro, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen-Idec, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma

    Research Support, Government Entities:

    1. Biogen-Idec, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Romain Casey, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Nadine Debard,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Bruno Stankoff, MD, PhD,
    6. Scientific Advisory Boards:

    1. advisory boards for Biogen Idec, Novartis, Genzyme, Teva-Pharma and Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. travel: EAN 2015 by TEVA, ECTRIMS 2016 by NOVARTIS lectures for TEVA, BIOGEN, NOVARTIS, GENZYME

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent pending for the identification of a compound that stimulate demyelination

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. research support from Merck-Serono and genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. research support from ANR (agence nationale de la recherche), PHRC (programme hospitalier de recherche clinique), fondation ARSEP and Progressive MS alliance

    Research Support, Foundations and Societies:

    1. grants from ARSEP fondation (association d e recherche sur la sclerose en plaques)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Serge Mrejen, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Zoe Uhry,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Eric Van Ganse, MD, PhD,
    9. Scientific Advisory Boards:

    1. Dr. Van Ganse reports grants and personal fees from ALK ABELLO, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, personal fees from IMS, personal fees from LASER, grants and personal fees from Merck Sharp and Dohme, outside the submitted work; .

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Van Ganse reports grants and personal fees from ALK ABELLO, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, personal fees from IMS, personal fees from LASER, grants and personal fees from Merck Sharp and Dohme, outside the submitted work; .

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Anne Castot, PhD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Michel Clanet, MD, PhD,
    11. Scientific Advisory Boards:

    1. Biogenidec; Genzyme, Merck Serono, Sanofi, Teva

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. ECTRIMS travel for annual meetings

    Editorial Boards:

    1. Multiple Sclerosis Journal without compensation until 2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. ARSEP ( Foundation for research in Multiple Sclerosis) EDMUS Eugene DEVIC Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Catherine Lubetzki, MD, PhD‡,
    12. Scientific Advisory Boards:

    1. VERTEX , BIOGEN, NOVARTIS, GENZYME

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate editor BRAIN editorial board member of MSJ and MSJ and related disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. BIOGEN, ROCHE, GENZYME

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. scientific collaboration with EMD SERONO

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Christian Confavreux, MD, PhD†,‡;
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. For the TYSEDMUS and OFSEP Group
    1. From the Neurology Department (C.P., S.M., C.L.), Pitié-Salpêtrière Hospital, Paris; Service de Neurologie A, Hôpital Neurologique Pierre Wertheimer (S.V., C.C.), and Neuro-epidemiology and Pharmaco-epidemiology (E.V.G.), Hospices Civils de Lyon, Lyon/Bron; Centre des Neurosciences de Lyon (S.V., C.C.), INSERM 1028 et CNRS UMR5292, Equipe Neuro-oncologie et Neuro-inflammation; Université de Lyon (S.V., C.C.); Observatoire Français de la Sclérose en Plaques (R.C., N.D., Z.U.), Bron; Neurology Department (B.S.), Saint Antoine Hospital, Paris; Agence Nationale de Sécurité des Médicaments (ANSM, formerly Agence Française de Sécurité Sanitaire des Produits de Santé—AFSSAPS) (A.C.), Saint-Denis; and Neurology Department (M.C.), Purpan Hospital, Toulouse, France.
    1. Correspondence to Dr. Papeix: caroline.papeix{at}psl.aphp.fr

    Article usage

    Article usage: October 2016 to October 2023

    AbstractFullPdfSource
    Oct 20164206Highwire
    Nov 201618910555Highwire
    Nov 201606931pmc
    Dec 20162644274Highwire
    Dec 201607538pmc
    Jan 201712248818Highwire
    Jan 201703714pmc
    Feb 2017691816Highwire
    Feb 201703510pmc
    Mar 201734449Highwire
    Mar 201703918pmc
    Apr 20173084Highwire
    Apr 2017152929pmc
    May 201723118Highwire
    May 201763031pmc
    Jun 20171757Highwire
    Jun 201773537pmc
    Jul 2017963Highwire
    Jul 201753539pmc
    Aug 20171396Highwire
    Aug 2017133956pmc
    Sep 2017617Highwire
    Sep 201774043pmc
    Oct 20171165Highwire
    Oct 201763238pmc
    Nov 20171689Highwire
    Nov 201775465pmc
    Dec 2017376Highwire
    Jan 20182136Highwire
    Feb 20180163Highwire
    Mar 20180231Highwire
    Apr 201812313Highwire
    Apr 2018114851pmc
    May 20181298Highwire
    Jun 20180304Highwire
    Jun 201855060pmc
    Jul 20180284Highwire
    Aug 20181354Highwire
    Aug 201855562pmc
    Sep 20181205Highwire
    Oct 20183307Highwire
    Nov 20181155Highwire
    Dec 20182198Highwire
    Jan 20190123Highwire
    Feb 20191105Highwire
    Mar 20195207Highwire
    Apr 20191418Highwire
    May 20196275Highwire
    Jun 20194548Highwire
    Jul 20193247Highwire
    Aug 20192186Highwire
    Sep 20191143Highwire
    Oct 20190163Highwire
    Nov 20190196Highwire
    Dec 20192122Highwire
    Jan 20202105Highwire
    Feb 20201166Highwire
    Mar 202041713Highwire
    Apr 20200113Highwire
    May 20200134Highwire
    Jun 2020183Highwire
    Jul 202012011Highwire
    Aug 20202265Highwire
    Sep 20201339Highwire
    Oct 202043711Highwire
    Nov 20201316Highwire
    Dec 20206569Highwire
    Jan 202166116Highwire
    Feb 20211306Highwire
    Mar 20211347Highwire
    Apr 20212413Highwire
    May 20215357Highwire
    Jun 20218444Highwire
    Jul 202114519Highwire
    Aug 20212326Highwire
    Sep 202112417Highwire
    Oct 202132426Highwire
    Nov 202121914Highwire
    Dec 202113010Highwire
    Jan 20220217Highwire
    Feb 20222364Highwire
    Mar 20222547Highwire
    Apr 202202830Highwire
    May 202227013Highwire
    Jun 20222157Highwire
    Jul 20228187Highwire
    Aug 20226265Highwire
    Sep 202253412Highwire
    Oct 20224326Highwire
    Nov 202286823Highwire
    Dec 202223210Highwire
    Jan 202384811Highwire
    Feb 20235255Highwire
    Mar 20232107Highwire
    Apr 20234104Highwire
    May 20235218Highwire
    Jun 20231135Highwire
    Jul 20231108Highwire
    Aug 2023254Highwire
    Sep 20232216Highwire
    Oct 20231213Highwire

    Letters: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. [email protected]
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Topics Discussed

    Alert Me

    Recommended articles